[The preventive effect of granisetron on digestive tract symptoms induced by arterial infusion of anticancer and hypertensive agents in combination with radiotherapy--a study of forty patients with bladder cancer].
Forty patients with bladder cancer who underwent radiotherapy with angiotensin II, a hypertensor, and two cycles of arterial infusion of anticancer chemotherapies, including cisplatin 100 mg/body, were randomly assigned to a granisetron group and a non-granisetron group for comparative study of its prophylactic effect on nausea, vomiting and anorexia. Granisetron proved significantly effective in preventing nausea, as 75% of granisetron-administered patients experienced either only slight nausea or none at all, against only 22.5% in the non-granisetron group. The number of vomiting episodes was zero during the three-day observation period in 28 out of 40 (70%) granisetron-administered patients compared with 6 patients (15%) in the non-granisetron group. A significant difference in prophylactic effect on anorexia was demonstrated between the granisetron and non-granisetron group, indicating that control of alimentary symptoms such as nausea and vomiting influences the severity of anorexia. As to the safety, nausea was lengthened and deteriorated in one patients. Though the physician in charge judged it to be an adverse event too minor to question the safety of granisetron. Thus, granisetron proved to be highly effective and safe in preventing nausea, vomiting and anorexia in patients under concomitant administration of radiotherapy with hypertensor and arterial infusion of anticancer chemotherapies.
Hayashida
S
S
Total Medical Center of Urology, Tokuyama Central Hospital.
Hirasawa
T
T
Uchiyama
K
K
Mitsui
H
H
Nasu
T
T
Shinohara
Y
Y
D000368:Aged; D000804:Angiotensin II / Q000187:drug effects / Q000494:pharmacology; D000855:Anorexia / Q000517:prevention & control*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001794:Blood Pressure; D002648:Child; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D005260:Female; D017829:Granisetron / Q000627:therapeutic use*; D006801:Humans; D007261:Infusions, Intra-Arterial; D008775:Methylprednisolone / Q000008:administration & dosage; D009325:Nausea / Q000517:prevention & control*; D005641:Tegafur / Q000008:administration & dosage / Q000009:adverse effects; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000503:physiopathology / Q000532:radiotherapy*; D014839:Vomiting / Q000517:prevention & control*
D000804:Angiotensin II; D002945:Cisplatin; D004317:Doxorubicin; D017829:Granisetron; D008775:Methylprednisolone; D005641:Tegafur; C027260:pirarubicin